Stay updated with breaking news from Randomized Controlled Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Frexalimab, a second-generation CD40L blocker, safely reduced the number of new active brain lesions in relapsing MS patients in a Phase 2 trial.
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications for a new indication to the U.S. Food and Drug Administration (FDA) and...
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from U-EXCEL, a Phase 3 induction study, showing upadacitinib (45 mg once daily)...
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from the first of two studies of the Phase 3 SELECT-AXIS 2 clinical trial...
ABBVie today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiographic axial spondyloarthritis showing upadacitinib met the primary endpoint of Assessment in SpondyloArthritis International Society 40 response and the majority of ranked secondary endpoints at week 14. 1 Significantly more upadacitinib-treated patients achieved ASAS40 ...